Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a

Journal of Experimental Medicine

Volumn 213, Issue 11, 2016, Pages 2399-2412

  Cheung, Ka Lun ^a   Jarrett, Rachael ^a   Subramaniam, Sumithra ^a   Salimi, Maryam ^a   Gutowska Owsiak, Danuta ^a   Chen, Yi Ling ^a   Hardman, Clare ^a   Xue, Luzheng ^b   Cerundolo, Vincenzo ^a   Ogg, Graham ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BAICALEIN; CLATHRIN; INDOMETACIN; INTERLEUKIN 17; INTERLEUKIN 22; LIPID; PHOSPHOLIPASE A2; T6 ANTIGEN; CD1 ANTIGEN; PHOSPHOLIPASE A2 GROUP IV; PLA2G4D PROTEIN, HUMAN;

ANTIGEN RECOGNITION; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; ENDOCYTOSIS; ENZYME ACTIVITY; EXOSOME; HUMAN; HUMAN CELL; K-562 CELL LINE; LAD 2 CELL LINE; MAST CELL; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN BIOPSY; T LYMPHOCYTE; ANTIGEN PRESENTATION; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; CYTOSOL; ENZYMOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SKIN;

ANTIGEN PRESENTATION; ANTIGENS, CD1; CASE-CONTROL STUDIES; CLATHRIN; COHORT STUDIES; CYTOSOL; ENDOCYTOSIS; EXOSOMES; GROUP IV PHOSPHOLIPASES A2; HUMANS; K562 CELLS; LIPIDS; LYMPHOCYTE ACTIVATION; MAST CELLS; PSORIASIS; SKIN; T-LYMPHOCYTES;

EID: 85017204228     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/JEM.20160258     Document Type: Article

References (75)

1. Amaya, M., M. Tajima, Y. Okubo, T. Sugita, A. Nishikawa, and R. Tsuboi. 2007. Molecular analysis of Malassezia microflora in the lesional skin of psoriasis patients. J. Dermatol. 34:619-624. http://dx.doi.org/10.1111/j.1346-8138.2007.00343.x
2. Andersen, S., W. Sjursen, A. Laegreid, G. Volden, and B. Johansen. 1994. Elevated expression of human nonpancreatic phospholipase A2 in psoriatic tissue. Inflammation. 18:1-12. http://dx.doi.org/10.1007/BF01534593
3. Arakawa, A., K. Siewert, J. Stöhr, P. Besgen, S.M. Kim, G. Rühl, J. Nickel, S. Vollmer, P. Thomas, S. Krebs, et al. 2015. Melanocyte antigen triggers autoimmunity in human psoriasis. J. Exp. Med. 212:2203-2212. http://dx.doi.org/10.1084/jem.20151093
4. Austin, L.M., M. Ozawa, T. Kikuchi, I.B. Walters, and J.G. Krueger. 1999. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-?, interleukin-2, and tumor necrosis factor-a, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113:752-759. http://dx.doi.org/10.1046/j.1523-1747.1999.00749.x
5. Balato, A., S. Lembo, M. Mattii, M. Schiattarella, R. Marino, A. De Paulis, N. Balato, and F. Ayala. 2012. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp. Dermatol. 21:892-894. http://dx.doi.org/10.1111/exd.12027
6. Birkinshaw, R.W., D.G. Pellicci, T.Y. Cheng, A.N. Keller, M. Sandoval-Romero, S. Gras, A. de Jong, A.P. Uldrich, D.B. Moody, D.I. Godfrey, and J. Rossjohn. 2015. aß T cell antigen receptor recognition of CD1a presenting self lipid ligands. Nat. Immunol. 16:258-266. http://dx.doi.org/10.1038/ni.3098
7. Bourgeois, E.A., S. Subramaniam, T.Y. Cheng, A. De Jong, E. Layre, D. Ly, M. Salimi, A. Legaspi, R.L. Modlin, M. Salio, et al. 2015. Bee venom processes human skin lipids for presentation by CD1a. J. Exp. Med. 212:149-163. http://dx.doi.org/10.1084/jem.20141505
8. Brody, I. 1984. Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris. J. Invest. Dermatol. 82:460-464. http://dx.doi.org/10.1111/1523-1747.ep12260955
9. Cafarchia, C., and D. Otranto. 2004. Association between phospholipase production by Malassezia pachydermatis and skin lesions. J. Clin. Microbiol. 42:4868-4869. http://dx.doi.org/10.1128/JCM.42.10.4868.-4869.2004
10. Chiba, H., H. Michibata, K. Wakimoto, M. Seishima, S. Kawasaki, K. Okubo, H. Mitsui, H. Torii, and Y. Imai. 2004. Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2d, induced in psoriatic skin. J. Biol. Chem. 279:12890-12897. http://dx.doi.org/10.1074/jbc.M305801200
11. Cumberbatch, M., M. Singh, R.J. Dearman, H.S. Young, I. Kimber, and C.E. Griffiths. 2006. Impaired Langerhans cell migration in psoriasis. J. Exp. Med. 203:953-960. http://dx.doi.org/10.1084/jem.20052367
12. de Jong, A., V. Peña-Cruz, T.Y. Cheng, R.A. Clark, I. Van Rhijn, and D.B. Moody. 2010. CD1a-autoreactive T cells are a normal component of the human aß T cell repertoire. Nat. Immunol. 11:1102-1109. http://dx.doi.org/10.1038/ni.1956
13. de Jong, A., T.Y. Cheng, S. Huang, S. Gras, R.W. Birkinshaw, A.G. Kasmar, I. Van Rhijn, V. Peña-Cruz, D.T. Ruan, J.D. Altman, et al. 2014. CD1aautoreactive T cells recognize natural skin oils that function as headless antigens. Nat. Immunol. 15:177-185. http://dx.doi.org/10.1038/ni.2790
14. Denzer, K., M.J. Kleijmeer, H.F. Heijnen, W. Stoorvogel, and H.J. Geuze. 2000. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J. Cell Sci. 113:3365-3374
15. Dougan, S.K., A. Kaser, and R.S. Blumberg. 2007. CD1 expression on antigen-presenting cells. Curr. Top. Microbiol. Immunol. 314:113-141
16. Dyring-Andersen, B., C. Geisler, C. Agerbeck, J.P. Lauritsen, S.D. Gúdjonsdottir, L. Skov, and C.M. Bonefeld. 2014. Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br. J. Dermatol. 170:609-616. http://dx.doi.org/10.1111/bjd.12658
17. Eaton, L.H., L. Chularojanamontri, F.R. Ali, E. Theodorakopoulou, R.J. Dearman, I. Kimber, and C.E. Griffiths. 2014. Guttate psoriasis is associated with an intermediate phenotype of impaired Langerhans cell migration. Br. J. Dermatol. 171:409-411. http://dx.doi.org/10.1111/bjd.12960
18. Forster, S., E. Ilderton, R. Summerly, and H.J. Yardley. 1983a. Epidermal phospholipase A2 activity is raised in the uninvolved skin of psoriasis. Br. J. Dermatol. 109:30-35. http://dx.doi.org/10.1111/j.1365-2133.1983.tb06815.x
19. Forster, S., E. Ilderton, R. Summerly, and H.J. Yardley. 1983b. The level of phospholipase A2 activity is raised in the uninvolved epidermis of psoriasis. Br. J. Dermatol. 108:103-105. http://dx.doi.org/10.1111/j.1365-2133.1983.tb04585.x
20. Forster, S., E. Ilderton, J.F. Norris, R. Summerly, and H.J. Yardley. 1985. Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. Br. J. Dermatol. 112:135-147. http://dx.doi.org/10.1111/j.1365.-2133.1985.tb00077.x
21. Gelfand, J.M., R.S. Stern, T. Nijsten, S.R. Feldman, J. Thomas, J. Kist, T. Rolstad, and D.J. Margolis. 2005. The prevalence of psoriasis in African Americans: results from a population-based study. J. Am. Acad. Dermatol. 52:23-26. http://dx.doi.org/10.1016/j.jaad.2004.07.045
22. Ghosh, M., R. Loper, M.H. Gelb, and C.C. Leslie. 2006. Identification of the expressed form of human cytosolic phospholipase A2ß (cPLA2ß): cPLA2ß3 is a novel variant localized to mitochondria and early endosomes. J. Biol. Chem. 281:16615-16624. http://dx.doi.org/10.1074./jbc.M601770200
23. Gottlieb, A.B., R.G. Langley, S. Philipp, B. Sigurgeirsson, A. Blauvelt, R. Martin, C. Papavassilis, and S. Mpofu. 2015. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: Results from two randomized, phase 3 trials. J. Drugs Dermatol. 14:821-833
24. Griffiths, C.E., and J.N. Barker. 2007. Pathogenesis and clinical features of psoriasis. Lancet. 370:263-271. http://dx.doi.org/10.1016/S0140.-6736(07)61128-3
25. Gumperz, J.E. 2006. The ins and outs of CD1 molecules: bringing lipids under immunological surveillance. Traffic. 7:2-13. http://dx.doi.org/10.1111/j.1600-0854.2005.00364.x
26. Hammarström, S., M. Hamberg, B. Samuelsson, E.A. Duell, M. Stawiski, and J.J. Voorhees. 1975. Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc. Natl. Acad. Sci. USA. 72:5130-5134. http://dx.doi.org/10.1073/pnas.72.12.5130
27. Henseler, T., and E. Christophers. 1995. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 32:982-986. http://dx.doi.org/10.1016/0190.-9622(95)91336-X
28. Hueber, W., D.D. Patel, T. Dryja, A.M. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M.H. Gold, P. Durez, et al. Uveitis Study Group. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2:52ra72. http://dx.doi.org/10.1126/scitranslmed.3001107
29. Izaki, S., T. Yamamoto, Y. Goto, S. Ishimaru, F. Yudate, K. Kitamura, and M. Matsuzaki. 1996. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Br. J. Dermatol. 134:1060-1064. http://dx.doi.org/10.1111/j.1365-2133.1996.tb07943.x
30. Jarrett, R., M. Salio, A. Lloyd-Lavery, S. Subramaniam, E. Bourgeois, C. Archer, K.L. Cheung, C. Hardman, D. Chandler, M. Salimi, et al. 2016. Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase. Sci. Transl. Med. 8:325ra18. http://dx.doi.org/10.1126/scitranslmed.aad6833
31. Johnston, A., J.E. Gudjonsson, H. Sigmundsdottir, T.J. Love, and H. Valdimarsson. 2004. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cells. Clin. Exp. Immunol. 138:83-93. http://dx.doi.org/10.1111/j.1365-2249.2004.00600.x
32. Kagami, S., H.L. Rizzo, J.J. Lee, Y. Koguchi, and A. Blauvelt. 2010. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130:1373-1383. http://dx.doi.org/10.1038/jid.2009.399
33. Katzmann, D.J., M. Babst, and S.D. Emr. 2001. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESC RT-I. Cell. 106:145-155. http://dx.doi.org/10.1016/S0092-8674(01)00434-2
34. Keijsers, R.R., I. Joosten, P.E. van Erp, H.J. Koenen, and P.C. van de Kerkhof. 2014. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp. Dermatol. 23:799-803. http://dx.doi.org/10.1111/exd.12487
35. Keller, S., M.P. Sanderson, A. Stoeck, and P. Altevogt. 2006. Exosomes: from biogenesis and secretion to biological function. Immunol. Lett. 107:102-108. http://dx.doi.org/10.1016/j.imlet.2006.09.005
36. Kimball, A.B., K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, and K.B. Gordon. PHO ENIX 1 Investigators. 2013. Long-term efficacy of ustekinumab in patients with moderateto-severe psoriasis treated for up to 5 years in the PHO ENIX 1 study. J. Eur. Acad. Dermatol. Venereol. 27:1535-1545. http://dx.doi.org/10.1111./jdv.12046
37. Kobayashi, H., M. Takahashi, H. Takahashi, A. Ishida-Yamamoto, Y. Hashimoto, K. Sato, M. Tateno, and H. Iizuka. 2002. CD4+ T-cells from peripheral blood of a patient with psoriasis recognize keratin 14 peptide but not 'homologous' streptococcal M-protein epitope. J. Dermatol. Sci. 30:240-247. http://dx.doi.org/10.1016/S0923-1811(02)00111-1
38. Krishnamoorthy, L., J.W. Bess Jr., A.B. Preston, K. Nagashima, and L.K. Mahal. 2009. HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat. Chem. Biol. 5:244-250. http://dx.doi.org/10.1038/nchembio.151
39. Lande, R., E. Botti, C. Jandus, D. Dojcinovic, G. Fanelli, C. Conrad, G. Chamilos, L. Feldmeyer, B. Marinari, S. Chon, et al. 2014. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 5:5621. http://dx.doi.org/10.1038/ncomms6621
40. Landgren, E., L. Bråbäck, G. Hedlin, A. Hjern, and F. Rasmussen. 2006. Psoriasis in Swedish conscripts: time trend and association with T-helper 2-mediated disorders. Br. J. Dermatol. 154:332-336. http://dx.doi.org/10.1111/j.1365-2133.2005.07004.x
41. Lebwohl, M., B. Strober, A. Menter, K. Gordon, J. Weglowska, L. Puig, K. Papp, L. Spelman, D. Toth, F. Kerdel, et al. 2015. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N. Engl. J. Med. 373:1318-1328. http://dx.doi.org/10.1056/NEJMoa1503824
42. Leslie, C.C. 2004. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot. Essent. Fatty Acids. 70:373-376. http://dx.doi.org/10.1016/j.plefa.2003.12.012
43. Leslie, C.C., and M.H. Gelb. 2004. Assaying phospholipase A2 activity. Methods Mol. Biol. 284:229-242
44. Leung, D.Y., J.B. Travers, R. Giorno, D.A. Norris, R. Skinner, J. Aelion, L.V. Kazemi, M.H. Kim, A.E. Trumble, M. Kotb, et al. 1995. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. 96:2106-2112. http://dx.doi.org/10.1172/JCI118263
45. Lin, A.M., C.J. Rubin, R. Khandpur, J.Y. Wang, M. Riblett, S. Yalavarthi, E.C. Villanueva, P. Shah, M.J. Kaplan, and A.T. Bruce. 2011. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187:490-500. http://dx.doi.org/10.4049/jimmunol.1100123
46. Lowes, M.A., T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L.C. Zaba, A.S. Haider, E.P. Bowman, and J.G. Krueger. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128:1207-1211. http://dx.doi.org/10.1038/sj.jid.5701213
47. Morelli, A.E., A.T. Larregina, W.J. Shufesky, M.L. Sullivan, D.B. Stolz, G.D. Papworth, A.F. Zahorchak, A.J. Logar, Z. Wang, S.C. Watkins, et al. 2004. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood. 104:3257-3266. http://dx.doi.org/10.1182/blood-2004-03-0824
48. Mori, L., and G. De Libero. 2008. Presentation of lipid antigens to T cells. Immunol. Lett. 117:1-8. http://dx.doi.org/10.1016/j.imlet.2007.11.027
49. Nestle, F.O., C. Conrad, A. Tun-Kyi, B. Homey, M. Gombert, O. Boyman, G. Burg, Y.J. Liu, and M. Gilliet. 2005. Plasmacytoid predendritic cells initiate psoriasis through interferon-a production. J. Exp. Med. 202:135-143. http://dx.doi.org/10.1084/jem.20050500
50. Ohto, T., N. Uozumi, T. Hirabayashi, and T. Shimizu. 2005. Identification of novel cytosolic phospholipase A2s, murine cPLA2d, e, and ?, which form a gene cluster with cPLA2ß. J. Biol. Chem. 280:24576-24583. http://dx.doi.org/10.1074/jbc.M413711200
51. Papp, K.A., R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, C. Guzzo, M.C. Hsu, Y. Wang, S. Li, et al. PHO ENIX 2. study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHO ENIX 2). Lancet. 371:1675-1684. http://dx.doi.org/10.1016/S0140-6736(08)60726-6
52. Papp, K.A., C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, G. Kricorian, G. Aras, J. Li, C.B. Russell, E.H. Thompson, and S. Baumgartner. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366:1181-1189. http://dx.doi.org/10.1056/NEJMoa1109017
53. Papp, K., A. Menter, B. Strober, G. Kricorian, E.H. Thompson, C.E. Milmont, A. Nirula, and P. Klekotka. 2015. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 72:436-439.e1. http://dx.doi.org/10.1016/j.jaad.2014.10.026
54. Quaranta, M., B. Knapp, N. Garzorz, M. Mattii, V. Pullabhatla, D. Pennino, C. Andres, C. Traidl-Hoffmann, A. Cavani, F.J. Theis, et al. 2014. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Sci. Transl. Med. 6:244ra90. http://dx.doi.org/10.1126/scitranslmed.3008946
55. Res, P.C., G. Piskin, O.J. de Boer, C.M. van der Loos, P. Teeling, J.D. Bos, and M.B. Teunissen. 2010. Overrepresentation of IL-17A and IL-22. producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 5:e14108. http://dx.doi.org/10.1371/journal.pone.0014108
56. Ryborg, A.K., B. Grøn, and K. Kragballe. 1995. Increased lysophosphatidylcholine content in lesional psoriatic skin. Br. J. Dermatol. 133:398-402. http://dx.doi.org/10.1111/j.1365-2133.1995.tb02667.x
57. Schön, M.P. 2014. The plot thickens while the scope broadens: a holistic view on IL-17 in psoriasis and other inflammatory disorders. Exp. Dermatol. 23:804-806. http://dx.doi.org/10.1111/exd.12541
58. Schorey, J.S., and S. Bhatnagar. 2008. Exosome function: from tumor immunology to pathogen biology. Traffic. 9:871-881. http://dx.doi.org/10.1111/j.1600-0854.2008.00734.x
59. Schubert, C., and E. Christophers. 1985. Mast cells and macrophages in early relapsing psoriasis. Arch. Dermatol. Res. 277:352-358. http://dx.doi.org/10.1007/BF00509232
60. Shaw, F.L., K.T. Mellody, S. Ogden, R.J. Dearman, I. Kimber, and C.E. Griffiths. 2014. Treatment-related restoration of Langerhans cell migration in psoriasis. J. Invest. Dermatol. 134:268-271. http://dx.doi.org/10.1038/jid.2013.289
61. Shefler, I., M. Pasmanik-Chor, D. Kidron, Y.A. Mekori, and A.Y. Hershko. 2014. T cell-derived microvesicles induce mast cell production of IL-24: relevance to inflammatory skin diseases. J. Allergy Clin. Immunol. 133:217-224.e3. http://dx.doi.org/10.1016/j.jaci.2013.04.035
62. Simons, M., and G. Raposo. 2009. Exosomes-vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 21:575-581. http://dx.doi.org/10.1016/j.ceb.2009.03.007
63. Simpson, R.J., J.W. Lim, R.L. Moritz, and S. Mathivanan. 2009. Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics. 6:267-283. http://dx.doi.org/10.1586/epr.09.17
64. Stoorvogel, W., M.J. Kleijmeer, H.J. Geuze, and G. Raposo. 2002. The biogenesis and functions of exosomes. Traffic. 3:321-330. http://dx.doi.org/10.1034/j.1600-0854.2002.30502.x
65. Subramaniam, S., A. Aslam, S.A. Misbah, M. Salio, V. Cerundolo, D.B. Moody, and G. Ogg. 2016. Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals. Eur. J. Immunol. 46:242-252. http://dx.doi.org/10.1002/eji.201545869
66. Teunissen, M.B., J.M. Munneke, J.H. Bernink, P.I. Spuls, P.C. Res, A. Te Velde, S. Cheuk, M.W. Brouwer, S.P. Menting, L. Eidsmo, et al. 2014. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients. J. Invest. Dermatol. 134:2351-2360. http://dx.doi.org/10.1038./jid.2014.146
67. Valdimarsson, H., B.S. Baker, I. Jónsdóttir, A. Powles, and L. Fry. 1995. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today. 16:145-149. http://dx.doi.org/10.1016./0167-5699(95)80132-4
68. van Niel, G., I. Porto-Carreiro, S. Simoes, and G. Raposo. 2006. Exosomes: a common pathway for a specialized function. J. Biochem. 140:13-21. http://dx.doi.org/10.1093/jb/mvj128
69. Verhagen, A., M. Bergers, P.E. van Erp, J.M. Gommans, P.C. van de Kerkhof, and P.D. Mier. 1984. Confirmation of raised phospholipase A2 activity in the uninvolved skin of psoriasis. Br. J. Dermatol. 110:731-732. http://dx.doi.org/10.1111/j.1365-2133.1984.tb04712.x
70. Villanova, F., B. Flutter, I. Tosi, K. Grys, H. Sreeneebus, G.K. Perera, A. Chapman, C.H. Smith, P. Di Meglio, and F.O. Nestle. 2014. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Invest. Dermatol. 134:984-991. http://dx.doi.org/10.1038/jid.2013.477
71. Vissers, W.H., L. Muys, P.E. Erp, E.M. de Jong, and P.C. van de Kerkhof. 2004. Immunohistochemical differentiation between inflammatory linear verrucous epidermal nevus (ILV EN) and psoriasis. Eur. J. Dermatol. 14:216-220
72. Vitiello, M., A. Tosti, A. Abuchar, M. Zaiac, and F.A. Kerdel. 2013. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients. Int. J. Dermatol. 52:358-362. http://dx.doi.org/10.1111/j.1365-4632.2011.05320.x
73. Yakimchuk, K., C. Roura-Mir, K.G. Magalhaes, A. de Jong, A.G. Kasmar, S.R. Granter, R. Budd, A. Steere, V. Pena-Cruz, C. Kirschning, et al. 2011. Borrelia burgdorferi infection regulates CD1 expression in human cells and tissues via IL1-ß. Eur. J. Immunol. 41:694-705. http://dx.doi.org/10.1002/eji.201040808
74. Zajonc, D.M., M.A. Elsliger, L. Teyton, and I.A. Wilson. 2003. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat. Immunol. 4:808-815. http://dx.doi.org/10.1038/ni948
75. Zajonc, D.M., M.D. Crispin, T.A. Bowden, D.C. Young, T.Y. Cheng, J. Hu, C.E. Costello, P.M. Rudd, R.A. Dwek, M.J. Miller, et al. 2005. Molecular mechanism of lipopeptide presentation by CD1a. Immunity. 22:209-219. http://dx.doi.org/10.1016/j.immuni.2004.12.009